Company ProfilePremium

Sequana Medical NV

Company Profile Analysis

Ticker: SEQUA.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sequana Medical NV - Company showcase

Year Founded & Workforce

2006

43 Employees

Sequana Medical NV logo

Sequana Medical NV Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sequana Medical NV Overview

Sequana Medical was a Ghent-headquartered, Zurich-manufacturing medical technology company that pioneered device- and drug-based treatments for diuretic-resistant fluid overload. Its flagship, the alfapump®, is a fully implanted, wirelessly charged pump that moves ascitic fluid from the abdomen to the bladder for natural voiding, and in December 2024 became the first active implantable device approved by the US FDA (PMA P230044) for recurrent or refractory ascites due to liver cirrhosis. A second platform, DSR® (Direct Sodium Removal), a sodium-free peritoneal infusate for cardiorenal syndrome in heart failure, reached Phase 1/2a. Despite regulatory success, CE-mark history since 2011, more than 1,000 implants and a US commercial launch in Q4 2025, the company never generated meaningful revenue, accumulated losses approaching EUR 270m, carried negative equity from 2021 onward and relied on serial dilutive financings. It filed for bankruptcy in June 2026; its value now resides in IP, regulatory dossiers, inventory and know-how being marketed by court-appointed trustees.


Company's own description (FY2024 results release / H1 2025 report, paraphrased). Sequana Medical described itself as a pioneer in treating fluid overload — a serious and frequent complication in liver disease, heart failure and cancer that drives mortality, repeat hospitalisation, pain, breathlessness and restricted mobility. Because diuretics become ineffective, intolerable or counter-productive in many patients, the company positioned its two proprietary platforms, alfapump® and DSR®, as working "with the body" to treat this diuretic-resistant population while reducing healthcare costs. In its final business descriptions (late 2025 to April 2026) the company emphasised US commercialisation of the alfapump through a specialty team targeting the ~90 US liver transplant centres that perform more than 90% of US liver transplants, CMS approval of a New Technology Add-on Payment (NTAP) from 1 October 2025, and a DSR randomised cohort that was approved by its DSMB but dependent on financing.

Independent characterisation. Functionally, Sequana was a pre-revenue, single-asset implantable-device company with an attached early-stage drug programme. Its economic engine was capital markets access rather than sales: across FY2021–FY2024 it generated EUR 2.1m of cumulative revenue against EUR 131.6m of cumulative net losses. The company's value chain position was that of an integrated OEM: it designed, assembled (Zurich), obtained regulatory approval for and (in the US) directly sold a Class III active implantable device, while DSR was being developed as a proprietary pharmaceutical-type infusate (DSR 2.0, a sodium-free dextrose/icodextrin solution) administered via peritoneal catheter. The strategic arc was: (1) build a European clinical and commercial base (2012–2023); (2) exit European sales in Q1 2024 to conserve cash; (3) pivot entirely to the US with PMA approval (Dec 2024) and a Q4 2025 launch; (4) attempt to finance DSR separately. The model failed on the time-to-revenue versus cash-runway equation rather than on regulatory or clinical evidence.

Business and revenue model.

Strategy

Stated strategy themes (latest disclosures, paraphrased). (1) Commercialise the alfapump in the US through a small specialty salesforce focused on ~90 liver transplant centres; (2) secure and leverage US reimbursement (CPT III, ICD-10, NTAP); (3) a two-phase US rollout — "Soft Launch" (≥70 implants at up to eight centres through end-Q1 2026) followed by "Full Launch" from Q2 2026 adding about five centres per quarter; (4) finance DSR separately, either within the company or as a standalone entity, to broaden the investor universe; (5) reduce cash burn and convert debt into equity.

Strategic initiatives register (last 24 months)

ESG/sustainability commitments: none publicly disclosed. Medium-term financial targets: none beyond implant and centre-opening targets.

Products & Services

alfapump® System (liver / oncology programme)

AttributeDetail
DescriptionFully implanted, programmable, wirelessly charged, battery-powered subcutaneous pump that automatically and continuously moves ascites from the peritoneal cavity to the bladder for elimination by urination
Regulatory — USFDA Breakthrough Device designation (2019); PMA approval 20 Dec 2024 (P230044) for adult patients with recurrent or refractory ascites due to liver cirrhosis; first US-approved active implantable device (Class III) for this indication
Regulatory — EUCE mark 2011 (refractory ascites due to cirrhosis); CE-marked also for malignant ascites; MDR certification by BSI, Feb 2022
Regulatory — CanadaNot approved
Key evidencePOSEIDON (18 centres US/Canada; pivotal cohort 40 patients): 100% median per-patient reduction in therapeutic paracentesis at 6 months; 77% with ≥50% reduction; virtual elimination of paracentesis sustained to 24 months; QoL improvement (SF-36 PCS, Ascites Q); ~10 additional good-health days per month; 24-month overall survival 62% in pivotal cohort (AASLD Nov 2024); published American Journal of Gastroenterology Jan 2025. Post-hoc EASL 2026: 10 of 48 patients with functioning pump at 6 months achieved recompensation (median 519 days). European PMSR published Liver International (2022)
Safety profileSix primary safety events in pivotal cohort (three explants for wound/skin erosion, three for patient-reported discomfort); MRI unsafe; risks include infection, peritonitis, pump migration, catheter complications, renal function decline, hepatic encephalopathy
Installed base>1,000 implants worldwide (company, 2025)
Target customerUS liver transplant centres (90 centres performing >90% of transplants); hepatologists and interventional radiologists
Launch / latest versionEU launch 2012; US commercial launch Q4 2025 (first implant 24 Nov 2025)
Pricing modelCapital-free per-unit sale; anticipated US ASP ~USD 30,000; NTAP top-up up to USD 21,450
Named commercial sites (US)Mount Sinai Hospital (NY), University of Pennsylvania, an unnamed "leading US liver transplant centre", Dartmouth Hitchcock Medical Center, University Medical Center of Southern Nevada

DSR® (Direct Sodium Removal) — heart failure programme

AttributeDSR 1.0DSR 2.0
DescriptionFirst-generation sodium-free infusate (used with alfapump-based delivery originally, then catheter)Proprietary sodium-free dextrose/icodextrin solution administered via peritoneal catheter; short-term intensive therapy (3–4 weeks) aimed at ≥12 months of benefit
MechanismDiffusion of sodium into sodium-free peritoneal infusate, removed with fluid; positioned as breaking the cardiorenal vicious cycle and restoring diuretic responseSame, with improved efficiency and safety vs dextrose-based solutions (Kidney Medicine, Nov 2024)
StudiesRED DESERT (PoC, 2021), SAHARA Phase 2a (top-line Nov 2022); both in European Journal of Heart Failure (Apr 2024)YUKON (Canada) and CHIHUAHUA (Mexico) Phase 1 single-dose; GLP studies in mice and sheep (Feb 2023); MOJAVE US Phase 1/2a — 3 non-randomised patients: mean +326% six-hour urinary sodium excretion and 95% reduction in loop diuretics at 3 months (Mar 2024); randomised cohort of up to 30 patients DSMB-approved but never started for lack of funding
StatusSupersededClinical stage; not approved anywhere; IP being sold by trustees
Target customerCardiologists / heart-failure centres; company estimated ~200,000 US HF patients with diuretic-resistant congestion (FY2022 results)Same

Other / discontinued

OfferingDetail
alfapump DSR (fully implanted DSR system)Original concept at IPO (2019) to combine alfapump with DSR; abandoned when DSR was shown to work without the pump — company stated little synergy remained between programmes (FY2024 results)
European alfapump salesGermany was historically the largest market; terminated Q1 2024

Financial Narrative

Source basis: FY2021–FY2022 from FY2022 results release (9 Feb 2023); FY2023–FY2024 from FY2024 results release (18 Mar 2025); FY2020 revenue and net loss from Euronext company data (Cofisem); FY2020 year-end cash and equity derived from opening balances in FY2022 release. FY2025 financial statements were never published; H1 2025 data presented separately. EBITDA computed as EBIT plus depreciation (cash-flow statement). Pre-tax income computed as net loss plus income tax expense.

Income statement: notes and sources

Note: diluted EPS not separately reported; with net losses, potential shares are anti-dilutive, so diluted equals basic.

Margins and growth

Revenue CAGR FY2020–FY2024: -42.4% (EUR 963k to EUR 106k). FY2021–FY2024 CAGR: -34.1%.

H1 2025 versus H1 2024 (last published financials)

Source: H1 2025 results release (25 Sep 2025).

Balance sheet

At 30 June 2025: total assets EUR 14,571k; cash EUR 7,314k; short-term financial debts EUR 40,426k; other current financial liabilities EUR 6,586k; total equity EUR -39,175k; losses brought forward EUR -268,954k; first capitalised development costs EUR 264k (IAS 38). Net debt decreased by EUR 2.2m versus end-2024 (H1 2025 report).

Note on working capital: the company described FY2024 and H1 2025 working capital as having "dropped" by EUR 1.44m and EUR 1.83m; arithmetically, the defined measure became less negative (from EUR -4,900k to EUR -3,461k in FY2024), reflecting reduced payables and accruals as spending was cut. The discrepancy is one of sign convention.

Ratios

ROE, ROIC, debt/equity, net debt/EBITDA and interest coverage are not meaningful (negative equity from FY2021 and negative EBIT/EBITDA in every year). Cash conversion cycle is not meaningful given negligible revenue.

Commentary on trends, inflections and drivers

Revenue. Revenue was never a meaningful driver. The FY2022 rebound (EUR 923k) reflected post-COVID resumption of European implants; FY2023 declined as the company deliberately scaled back European selling to concentrate resources on US approval; and the Q1 2024 decision to terminate European commercial activities reduced revenue to EUR 106k in FY2024 and zero in H1 2025. US commercial revenue began only in Q4 2025 and was never reported because FY2025 accounts were not published. Gross margins in the 75–79% range are consistent with an implantable device priced around EUR 20–25k per unit in Europe, but on tiny volumes they are analytically irrelevant.

Operating expenses. The cost base rose from EUR 24.1m (FY2021) to a peak of EUR 30.0m (FY2023) as the company ran the POSEIDON pivotal study, prepared the PMA, and advanced DSR through SAHARA, GLP toxicology and MOJAVE start-up. The FY2024 inflection — a 37% cut to EUR 18.8m — was driven by the end of POSEIDON costs, postponement of the MOJAVE randomised cohort, the European commercial exit, headcount reductions and one-off FY2023 PMA-preparation spend not recurring. H1 2025 opex fell a further 9% even as US launch spending (S&M +91%, supply chain +18%) began, implying an annualised run-rate around EUR 18m — still far above any plausible near-term revenue.

Below-the-line volatility. The net loss widened to EUR 44.7m in FY2024 despite a smaller EBIT loss because of EUR 26.2m of net finance expense, overwhelmingly non-cash fair-value remeasurements of the Kreos loan (as amended in 2024), the September–December 2024 convertible loans and subscription rights (warrants). The same dynamic recurred in H1 2025 (net finance cost EUR 9.6m). These charges are symptomatic of a capital structure layered with convertible and warrant-bearing instruments whose fair values rose as the equity value of the conversion features changed.

Balance sheet. Equity turned negative in FY2021 and deteriorated to EUR -44.4m by FY2024. Total financial debt more than doubled in FY2024 to EUR 40.1m, all classified as current, reflecting fair-value accounting and loan maturity profiles. The company disclosed that, excluding the EUR 4.5m converted on 24 January 2025 and assuming conversion of remaining 2024 convertibles, the underlying principal, interest and fees at end-2024 would have been EUR 13.03m — a material gap between accounting and contractual debt that should inform any recovery analysis. Statutory (Belgian GAAP) net equity was also negative, triggering the Article 7:228 alarm-bell procedure at the May 2026 AGM.

Cash and going concern. Every set of accounts from FY2022 onward carried a material-uncertainty going-concern statement. Year-end cash covered between roughly one and eight months of operating outflows. Financing was obtained in increasingly small and increasingly structured tranches (mandatory convertibles, subordinated convertibles, an equity line with GEM), with runway guidance repeatedly extended by a quarter or two at a time: into Q1 2025 (late 2024), to end-2025 (March 2025), and to at least Q1 2026 (September 2025). The final runway expired in Q2 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionFunctionStatus (Oct 2026)

Sequana Medical NV

Belgium

Parent, registered office, listed entity

Bankrupt (30 Jun 2026)

Sequana Medical NV — Zurich branch

Switzerland

alfapump assembly, engineering, QA/RA, supply chain (35 employees)

Part of bankrupt estate (branch of NV)

DSRCo BV

Belgium

Vehicle for DSR programme / IP

Bankrupt (30 Jun 2026)

Sequana Medical US Inc

United States

US commercial operations (4 employees)

Status not publicly disclosed

Sequana Medical GmbH

Germany (implied)

Historic European commercial subsidiary (referenced in FY2024 statutory board report)

Status not publicly disclosed

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024

Total revenue — alfapump (EUR K)

371923712106

DSR programme revenue (EUR K)

0000

EBIT — total company (EUR K)

-22,614-28,094-28,862-18,223

Revenue YoY growth (%)

-61.5148.8-22.9-85.1

Share of total revenue — alfapump (%)

100100100100

Income Statement and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024

Revenue (EUR K)

963371923712106

Cost of goods sold (EUR K)

—-77-205-164-26

Gross profit (EUR K)

—29471854879

Sales & Marketing (EUR K)

—-2,079-2,240-1,799-1,058

Clinical (EUR K)

—-7,798-9,773-6,947-3,174

Quality & Regulatory (EUR K)

—-3,215-3,632-5,586-3,243

Supply Chain (EUR K)

—-2,716-3,158-4,724-3,315

Engineering (EUR K)

—-3,206-3,853-4,041-1,683

General & Administration (EUR K)

—-5,098-6,687-6,943-6,313

Total operating expenses (EUR K)

—-24,112-29,343-30,040-18,786

Other income (EUR K)

—1,205530629484

Operating income / EBIT (EUR K)

—-22,614-28,094-28,862-18,223

Depreciation (EUR K)

—409312661615

EBITDA (EUR K, computed)

—-22,205-27,782-28,201-17,608

Net finance result (EUR K)

—-608-2,282-3,236-26,150

Pre-tax income (EUR K, computed)

—-23,222-30,376-32,098-44,374

Income tax expense (EUR K)

—-393-387-466-280

Net income (EUR K)

-19,106-23,615-30,763-32,564-44,654

EPS basic (EUR)

—-1.30-1.35-1.22-1.22

EPS diluted (EUR)

—-1.30-1.35-1.22-1.22

Dividends per share (EUR)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024

Gross margin (%)

79.277.877.074.5

EBIT margin (%)

-6,095-3,044-4,054-17,192

EBITDA margin (%)

-5,985-3,010-3,961-16,611

Net margin (%)

-6,365-3,333-4,574-42,126

Revenue YoY growth (%)

-61.5148.8-22.9-85.1

Income Statement and Key Financials (EUR)

MetricH1 2024H1 2025

Revenue (EUR K)

1060

Total operating expenses (EUR K)

-9,816-8,966

EBIT (EUR K)

-9,595-8,582

Finance income (EUR K)

3,1723,193

Finance cost (EUR K)

-4,512-12,763

Net loss (EUR K)

-11,080-18,278

Basic LPS (EUR)

-0.34-0.35

Cash at period end (EUR K)

4,1537,314

Operating cash flow (EUR K)

-12,355-9,723

Financing cash flow (EUR K)

13,96213,258

Balance Sheet

MetricFY2020FY2021FY2022FY2023FY2024

Total assets (EUR K)

—14,70526,02510,1019,944

Cash and cash equivalents (EUR K)

11,0169,60018,8752,5843,807

Inventory (EUR K)

—2,1392,6212,2962,046

Short-term financial debt (EUR K)

—04,4837,81839,698

Long-term financial debt (EUR K)

—7,32512,1938,9690

Lease debt total (EUR K)

—760916733413

Other current financial liabilities (EUR K)

—01,5692,7677,387

Total financial and lease debt (EUR K)

—8,08517,60117,52040,111

Net debt (EUR K, company definition)

—-1,515-1,27414,93636,304

Total equity (EUR K)

113-787-2,153-19,465-44,379

Goodwill and intangibles (EUR K)

00000

Working capital (EUR K, company definition)

—-3,607-4,576-4,900-3,461

Accumulated losses brought forward (EUR K)

-119,080-142,695-173,458-206,022-250,676

Cash Flow

MetricFY2021FY2022FY2023FY2024

Operating cash flow (EUR K)

-23,617-27,482-29,063-20,258

Capex — tangible (EUR K)

-326-677-711-95

Free cash flow (EUR K, computed)

-23,943-28,159-29,774-20,353

Equity proceeds (EUR K)

22,77128,42015,78611,665

Debt proceeds (EUR K)

09,626010,682

Interest paid (EUR K)

0-315-929-162

Dividends paid (EUR K)

0000

Share buybacks (EUR K)

0000

Net change in cash (EUR K)

-1,5209,189-16,3241,197

Financial Ratios (x) and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024

Current ratio (x)

1.801.520.320.12

ROA (%, year-end assets)

-161-118-322-449

Asset turnover (x, year-end assets)

0.0250.0350.0700.011

Cash runway at year-end (months, cash / avg monthly operating outflow)

4.98.21.12.3

Revenue by Region

Region (EUR K)FY2022FY2023FY2024

Europe (all countries)

923712106

United States

000

Rest of world

000

Total

923712106

Region growth (%)

Region growth (%)FY2023FY2024

Europe

-22.9-85.1

Balance Sheet (FY2019–FY2025)

MetricFY2019FY2021FY2022FY2023FY2024FY2025

Gross equity / CLA financing raised (EUR Mn)

27.522.528.415.822.113.6

Share Price History

DatePrice (EUR)Event

11 Feb 2019

8.50

IPO price

Mar 2022

5.50

Equity placement price

27 Apr 2026

0.4581

GEM subscription price (last pre-suspension issuance reference)

28 Apr 2026 onward

Suspended

—

Valuation Snapshot

MultipleValue

P/E

Not meaningful (losses; bankrupt)

EV/Sales

Not meaningful (EUR 0.1m FY2024 revenue; FY2025 unpublished)

P/B

Not meaningful (negative book value)

Capital Markets

ItemDetail

Analyst coverage

Company listed analyst coverage page; Edison Investment Research (paid research client) published rNPV-based valuations (e.g., EUR 12.38/share in 2022; pipeline rNPV EUR 344m in Feb 2023); consensus not available post-suspension

Dividend history / policy

No dividends ever paid; none possible

Credit ratings

None (unrated)

Debt maturity profile

All financial debt classified current at FY2024 (EUR 39.7m short-term financial debt); contractual principal plus accrued interest and fees ~EUR 13.03m on a pro-forma basis after Jan 2025 conversions (FY2024 results). Detailed maturity ladder post-March 2025 restructuring not publicly disclosed. Now subject to bankruptcy claims process.

Analyst Conclusions

Management guidance. None outstanding. The last operational guidance (≥70 US implants at eight centres by end-Q1 2026, then ~5 new centres per quarter) was effectively withdrawn by the 28 April 2026 strategic review and superseded by the bankruptcy. Consensus growth expectations: none (coverage lapsed).

Bull case (for creditors / acquirers of the assets, not equity holders)

  1. An acquirer can buy an FDA-approved, NTAP-supported Class III device with pivotal data showing 100% median reduction in paracentesis, free of the EUR 40m accounting debt stack and the convertible/warrant overhang.

  2. The alfapump has >1,000 implants of clinical history, MDR certification and early US adopters (five centres, ~20 in pipeline as of Feb 2026), shortening a buyer's time to scale.

  3. DSR IP, backed by peer-reviewed RED DESERT/SAHARA data and a DSMB-approved randomised protocol, could attract a heart-failure strategic at modest cost.

Bear case

  1. Equity holders are very likely to receive nothing: statutory and IFRS equity are negative, creditors rank ahead and shares remain suspended.

  2. Asset value decays quickly in bankruptcy — the 35-person Zurich assembly team, hospital contracts and regulatory maintenance require funding the estate may not provide.

  3. Commercial traction was weak even before insolvency (single-digit implants against a 70-implant target), suggesting market adoption may be structurally slower than the company's USD 2bn opportunity framing implied.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict. Sequana Medical is a textbook case of regulatory success outrunning financial capacity. Over two decades the company did most of what a medtech innovator is supposed to do: it invented a genuinely novel device, built a European implant base, ran a well-executed North American pivotal study that exceeded its effectiveness endpoints, won FDA approval earlier than the market expected, secured CPT III codes and, critically, an NTAP worth up to USD 21,450 per inpatient case. It also generated a credible second platform in DSR with peer-reviewed evidence in diuretic-resistant heart failure. Yet none of this translated into revenue before the money ran out. The decision to exit Europe in 2024 removed the only income stream; the US launch began roughly a year after approval and then progressed through slow hospital value-analysis and contracting cycles; and the capital structure — negative equity since 2021, venture debt, mandatory and subordinated convertibles, warrants and a GEM equity line — made each successive raise smaller, more dilutive and more expensive. By April 2026 the company could not publish FY2025 accounts, and by June it could not meet obligations as they fell due. For equity investors, the analytical question is closed: the shares are suspended, book equity is deeply negative, and creditors rank ahead, so the expected recovery for shareholders is effectively zero. The more interesting question is for strategic acquirers and creditors. The alfapump's PMA, reimbursement codes, clinical dossier and installed base represent assets that cost well over EUR 200m to create and may now be acquired at a fraction of that, provided the Zurich know-how and US site relationships survive the bankruptcy timetable. DSR is an option for a cardiorenal specialist. The verdict: an investment failure, but a potentially valuable technology salvage — monitor the trustees' sale process, not the stock.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducation

Ian Crosbie

CEO; executive director

CEO since 2016; director since 2019

CFO, GC Aesthetics (Dublin); SVP Corporate Development, Circassia (led GBP 210m IPO); MD Healthcare Investment Banking, Jefferies; Director, Deutsche Bank

Engineering, Economics and Management, Oxford

Kirsten Van Bockstaele

CFO

—

VP Finance, Fagron North America; CFO, Arseus Dental & Medical Solutions; Omega Pharma; PwC

Business Economics (EHSAL); Financial and Fiscal Sciences (Antwerp)

Gijs Klarenbeek, MD

Chief Medical Officer

—

Director Medical Affairs Europe, Boston Scientific; Worldwide Medical Director Clinical Research, J&J (Cordis); Sanofi, AstraZeneca

MD (Leuven); business administration (IFB)

Martijn Blom

Chief Commercial Officer

—

Director International Marketing, Myriad Genetics; Pulmonx; Alere

Economics/marketing (Breda)

Mark Singer

Head of US Commercial (Florida)

Engaged since 2024; role from 2025

VP National Accounts, NuVasive; CCO, Carlsmed; CCO, Galen Robotics

—

Timur Resch

Global VP QM/QA/RA; PRRC

—

Medela; Schaerer Medical; Synspace

Medical technology engineering (Lübeck)

Andreas Wirth

VP Engineering

—

Director R&D, Carl Zeiss Meditec; Schott; medi Group; Lonza

PhD applied science; physics (Osnabrück)

Dragomir Lakic

Global VP Manufacturing

—

Smith+Nephew; Zimmer Biomet (12 years)

Engineering and Management; MBA (ZHAW)

“—” = not publicly disclosed.

Board of Directors

NameRoleIndependenceBackground

Pierre Chauvineau

Chair

Independent

20 years Medtronic; Cameron Health (acquired by Boston Scientific 2012); led Boston Scientific's largest European BU; chair of Aurigen Medical, Aryballe

Ian Crosbie

Executive director, CEO

Executive

See above

Rudy Dekeyser

Non-executive

Non-independent (EQT representative)

Partner, EQT; head of EQT Health Economics funds; VIB co-founder

Wim Ottevaere (WIOT BV)

Non-executive

Independent

Former CFO Biotalys, Ablynx, Innogenetics

Jackie Fielding

Non-executive

Independent

28 years Medtronic (VP UK/Ireland); NED at NICE

Alexandra Clyde

Non-executive

Independent

26 years Medtronic; Corporate SVP Global Health Economics, Policy and Reimbursement

Ids van der Weij

Non-executive

Non-independent (Partners in Equity V)

Managing Partner, Partners in Equity V

Major Shareholders

HolderNatureStake

Partners in Equity V B.V.

Lead investor since March 2022; 2024 and 2025 CLA lender

—

EQT Health Economics 3 Coöperatief U.A.

Shareholder (EQT lists entry 2024); 2025 CLA lender

—

SFPIM (Belgian Federal Holding and Investment Company)

Shareholder since IPO; 2025 CLA investor

—

Rosetta Capital

Acquired NeoMed V stake (2022/23); 2024 CLA

—

BlackRock Kreos (Kreos Capital)

Lender; equity via loan conversions and warrants; transparency notifications 8 Dec 2025 and 31 Dec 2025

—

GEM Global Yield LLC SCS

Equity line counterparty; transient holdings via subscriptions and share lending

—

Sensinnovat

2020 loan, partially converted Jan 2025

—

Historic VCs (LSP, VI Partners, BioMedPartners, Capricorn)

Pre-IPO investors

Current stakes not publicly disclosed

Insiders

Management and directors

—

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

Competitor / alternativeOwnerModalityPositioning versus alfapump

Large-volume (therapeutic) paracentesis

Standard of care; kits from multiple suppliers (e.g., BD, Cardinal Health)

Repeated needle drainage

Cheap, universal, but burdensome and repeated weekly/monthly; alfapump's core displacement target

TIPS (Viatorr stent-graft)

W. L. Gore & Associates (private)

Transjugular intrahepatic portosystemic shunt

Guideline-endorsed for refractory ascites; contraindicated or poorly tolerated in some patients (encephalopathy, liver function)

Tunnelled peritoneal catheters (PleurX)

BD

Indwelling drainage catheter

Used mainly in malignant ascites; infection risk

Aspira peritoneal drainage system

Merit Medical

Indwelling drainage catheter

Malignant/refractory ascites drainage

Rocket IPC

Rocket Medical

Indwelling drainage catheter

Malignant ascites

Long-term albumin infusion

Grifols, CSL Behring, Takeda, Octapharma

Plasma-derived therapy

Adjunct to paracentesis; evidence for outcomes in decompensated cirrhosis

Peritoneovenous (Denver) shunt

BD (CareFusion heritage)

Surgical shunt

Largely abandoned due to complications

Liver transplantation

Transplant centres

Definitive cure

Limited by organ supply; alfapump positioned as bridge

Emerging MASH/cirrhosis therapies

Madrigal (Rezdiffra), Novo Nordisk (semaglutide in MASH)

Disease-modifying drugs

Long-term could reduce progression to decompensation

Loop diuretics (furosemide, torsemide, bumetanide) and sequential nephron blockade

Generic

Pharmacological

Standard of care; diuretic resistance is DSR's target

Ultrafiltration (Aquadeus)

Nuwellis

Extracorporeal

Hospital-based fluid removal; mixed outcomes evidence

Reprieve System

Reprieve Cardiovascular

Automated decongestion with urine-matched fluid replacement

Clinical-stage competitor in acute decongestion

Aortix

Procyrion

Intra-aortic pump for cardiorenal syndrome

Clinical-stage

Peritoneal dialysis solutions (Extraneal icodextrin)

Baxter; Fresenius

Peritoneal therapy

Adjacent technology; DSR 2.0 uses icodextrin

SGLT2 inhibitors / finerenone

AstraZeneca, Boehringer Ingelheim/Lilly, Bayer

Pharmacological

Reduce HF hospitalisations broadly, shrinking diuretic-resistant pool

Peer Comparison FY2024

MetricSequana Medical (FY2024)BD (PleurX)Merit Medical (Aspira)

Revenue

EUR 0.1m

Diversified multi-billion group; product-line revenue not disclosed

Diversified group; product-line revenue not disclosed

Revenue growth

-85.1%

Not comparable

Not comparable

Gross margin

74.5%

Not comparable

Not comparable

Operating margin

-17,192%

Not comparable

Not comparable

R&D intensity (proxy)

7,642% of revenue

Not comparable

Not comparable

Company Snapshot

$0.1M

Revenue

43

Employees

$56M

Market Cap

2006

Founded

Sint-Denijs-Westrem, Belgium

Headquarters

SWOT Analysis

Strengths

  • Regulatory first-mover: FDA PMA approval on 20 December 2024 made alfapump the first US-approved active implantable device for recurrent/refractory ascites due to cirrhosis (FY2024 results).
  • Robust pivotal data: POSEIDON pivotal cohort showed 100% median reduction in therapeutic paracentesis and 77% of patients with ≥50% reduction at six months, sustained to 24 months (FY2022 results; AASLD 2024).
  • Reimbursement architecture in place: six CPT III codes (Jan 2024) and NTAP up to USD 21,450 from 1 October 2025 (H1 2025 report).
  • Long-term real-world experience: CE mark since 2011, >1,000 implants worldwide, MDR certification in February 2022.
  • Attractive unit economics in principle: gross margins of 75–79% (FY2021–FY2024) and anticipated US ASP of ~USD 30,000.
  • Second platform with published data: DSR results in European Journal of Heart Failure (Apr 2024) and Kidney Medicine (Nov 2024); DSMB-approved randomised MOJAVE cohort.

Weaknesses

  • Negligible revenue: EUR 106k in FY2024 and zero in H1 2025 after the European exit.
  • Structural losses: cumulative losses brought forward of EUR 268.95m at 30 June 2025; net loss EUR 44.65m in FY2024.
  • Negative equity: EUR -44.4m at end-2024 and EUR -39.2m at mid-2025; statutory equity negative, triggering Art. 7:228 (April 2026).
  • Short runways: year-end cash of EUR 2.6m (FY2023) and EUR 3.8m (FY2024) against ~EUR 20–29m annual operating outflows.
  • Execution shortfall: first US implant on 24 November 2025 versus "early Q4" guidance, and five centres by late February 2026 versus a target of ≥70 implants at eight centres by end-Q1 2026.
  • Complex, costly capital structure: fair-value charges of EUR 26.2m (FY2024) and EUR 9.6m (H1 2025) from convertibles, Kreos loan and warrants.

Opportunities

  • Transferable PMA and NTAP: an approved Class III device with an established reimbursement pathway can be acquired out of bankruptcy without the original capital structure (trustees' acquisition notice, 24 Jul 2026).
  • Growing patient pool: company forecasts 130,000 US RRA patients and >USD 5bn opportunity by 2035 (Feb 2026).
  • Early adopter centres: five US centres had implanted and ~20 more were in approval (Feb 2026), offering a commercial seed.
  • Recompensation signal: 10 of 48 patients with a functioning pump at six months achieved recompensation (EASL 2026), a potential differentiation and label-expansion narrative.
  • DSR standalone value: DSR IP offered separately by trustees; a heart-failure strategic could fund the 30-patient randomised cohort.
  • Malignant ascites: existing CE-marked indication could be leveraged in Europe by a buyer with an established salesforce.

Threats

  • Bankruptcy-driven value erosion: loss of staff (43 at bankruptcy), lapsed hospital contracts and potential supply interruption for implanted patients.
  • Shareholder wipe-out: shares suspended and characterised as worthless; creditors (Kreos, PMV, CLA holders) rank ahead.
  • Established alternatives: paracentesis and TIPS remain guideline standards; albumin therapy widely used.
  • Disease-modifying drugs: MASH therapies and GLP-1s may slow progression to decompensated cirrhosis over the long term.
  • Safety perception: explants for skin erosion and discomfort (3+3 of 40 in pivotal cohort) and MRI incompatibility may limit uptake.
  • Funding climate: company cited macroeconomic and geopolitical conditions as constraining financing (FY2022, FY2024 going-concern notes).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Apr 2025FY2024 annual report publishedGoing-concern material uncertainty reiterated
May 2025First GEM subscription request noticeActivation of equity line
22 May 2025AGM 2025Routine
26 May 2025SFPIM and existing shareholders add EUR 6.3m to 2025 CLA (total EUR 10.3m)Runway into Q1 2026; Belgian state investor support
Jul 2025Case report on alfapump-enabled umbilical hernia repair (*Hernia*)Clinical evidence
Aug 2025CMS FY2026 IPPS Final Rule approves NTAP (up to USD 21,450) from 1 Oct 2025Key US reimbursement win
Aug 2025GEM subscription request noticeDilutive funding
Sep 2025GEM subscription request noticeDilutive funding
25 Sep 2025H1 2025 results; EUR 2.0m further debt conversion; liquidity EUR 7.3m; Soft Launch target ≥70 implantsLast published financials
14 Oct 2025alfapump highlighted at SIR EDGE 2025Interventional radiology awareness
24 Nov 2025First US commercial implant, Mount Sinai (New York)Launch milestone, but ~1–2 months later than "early Q4" guidance
8 Dec 2025BlackRock Kreos transparency notificationShareholding threshold crossing (lender equity)
11 Dec 2025First commercial implants at University of Pennsylvania (two same day)Second centre
31 Dec 2025BlackRock Kreos transparency notification (published 6 Jan 2026)Further threshold change
27 Jan 2026New share capital and share count (74.5m shares)GEM settlement
2 Feb 2026GEM subscription request notice (settlement ~4 Mar 2026)Continued dilution
26 Feb 2026Five US centres implanting; ~20 more in approvalCommercial progress, far below Soft Launch target
5 Mar 2026Share capital update (GEM settlement)Dilution
26 Mar 2026New share capital; new GEM subscription request noticeDilution
27 Apr 2026598,149 shares issued to GEM at ~EUR 0.4581; 78.17m shares outstanding; Kreos warrant adjustmentShare price near EUR 0.46
28 Apr 2026Financial and strategic review; FY2025 accounts not available; statutory equity negative; trading suspendedDistress disclosure
28 May 2026AGM; accounts adjourned; Art. 7:228 continuation procedureGovernance under distress
29 May 2026POSEIDON recompensation post-hoc data at EASL 2026Last clinical communication
26 Jun 2026Board resolves to file for bankruptcy; requests FSMA maintain suspensionInsolvency
30 Jun 2026Ghent Enterprise Court bankruptcy judgment for NV and DSRCo BVLegal end of going concern
24 Jul 2026Trustees' announcement: 43 employees; asset sale process launchedValue-realisation phase
Jul 2026Belgian press (Made in, Test-Aankoop, De Aandeelhouder, MSN/Belga) report bankruptcy; Test-Aankoop states shares worthless and cites nearly EUR 200m losses over seven yearsShareholder outcome
Aug–Oct 2026No announced buyer for alfapump or DSR assets found in public sources as of 19 Oct 2026Monitorable

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit (FY2020–FY2024): Revenue fell from EUR 1 Mn in FY2020 to EUR 0.1 Mn in FY2024.
Sequana Medical NV — Income Statement: Revenue & Gross Profit (FY2020–FY2024)
Series (EUR Mn)FY2020FY2021FY2022FY2023FY2024
Revenue10.40.90.70.1
Cost of goods sold—-0.1-0.2-0.2-0
Gross profit—0.30.70.50.1
Sales & Marketing—-2.1-2.2-1.8-1.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Sequana Medical — Trustees' release "Sequana Medical NV and subsidiary DSRCo BV declared bankrupt by the Ghent Enterprise Court" (24 Jul 2026)
  2. Sequana Medical — Trustees' "Acquisition Opportunity — ALFAPUMP® and DSR® Assets" (24 Jul 2026)
  3. Sequana Medical — "Board decision to file for bankruptcy" (26 Jun 2026)
  4. Sequana Medical — "Financial and Strategic Review, Annual General Meeting, and Trading Halt" (28 Apr 2026)
  5. Sequana Medical — New share capital and number of shares (27 Apr 2026)
  6. Sequana Medical — Shareholder information (status 26 Jan 2026; transparency notifications)
  7. Sequana Medical — EASL 2026 recompensation presentation (29 May 2026)
  8. GlobeNewswire — US commercial progress, five centres (26 Feb 2026)
  9. GlobeNewswire — New share capital (27 Jan 2026)
  10. Finanznachrichten / GlobeNewswire — GEM subscription request notice (2 Feb 2026)
  11. Sequana Medical — University of Pennsylvania implants (11 Dec 2025)
  12. Sequana Medical — First US commercial implant, Mount Sinai (24 Nov 2025)
  13. Sequana Medical — SIR EDGE 2025 (14 Oct 2025)
  14. Sequana Medical — H1 2025 results and business update (25 Sep 2025)
  15. BioSpace — FY2024 results and 2025 outlook (18 Mar 2025)
  16. Sequana Medical — FY2024 statutory accounts board report
  17. Sequana Medical — FDA approval of alfapump (23 Dec 2024)
  18. Sequana Medical — H1 2024 results (30 Sep 2024)
  19. Sequana Medical — H1 2023 results (14 Sep 2023)
  20. BioSpace — FY2022 results and 2023 outlook (9 Feb 2023)
  21. Sequana Medical — Our history: Leadership · Board members · sequanamedical.com · sequanamedical.com
  22. Euronext — "Sequana Medical lists on Euronext Brussels" (11 Feb 2019)
  23. Van Lanschot Kempen — IPO tombstone (Feb 2019)
  24. Unquote — IPO price range and VC history (1 Feb 2019)
  25. Euronext company information (Cofisem data, FY2019–FY2023 net sales and net income)
  26. Made in (Belga) — "Sequana Medical failliet verklaard" (Jul 2026)
  27. Test-Aankoop Invest — "Sequana Medical vraagt faillissement aan" (Jul 2026)
  28. De Aandeelhouder — bankruptcy filing coverage (26 Jun 2026)
  29. PitchBook — company profile (secondary)
  30. CB Insights — patents count (secondary)
  31. Edison Investment Research — notes on Sequana Medical (paid research, secondary) · edisongroup.com
  32. EQT — portfolio page
  33. Beursduivel forum (unconfirmed speculation only)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.